- Home
- SUPN vs BANR Comparison
SUPN vs BANR Comparison
Compare SUPN & BANR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- BANR
- Stock Information
- Founded
- SUPN 2005
- BANR 1890
- Country
- SUPN United States
- BANR United States
- Employees
- SUPN N/A
- BANR N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- BANR Major Banks
- Sector
- SUPN Health Care
- BANR Finance
- Exchange
- SUPN Nasdaq
- BANR Nasdaq
- Market Cap
- SUPN 2.6B
- BANR 2.3B
- IPO Year
- SUPN 2012
- BANR 1995
- Fundamental
- Price
- SUPN $46.21
- BANR $66.61
- Analyst Decision
- SUPN Buy
- BANR Buy
- Analyst Count
- SUPN 2
- BANR 5
- Target Price
- SUPN $43.00
- BANR $70.75
- AVG Volume (30 Days)
- SUPN 707.2K
- BANR 153.0K
- Earning Date
- SUPN 11-03-2025
- BANR 10-15-2025
- Dividend Yield
- SUPN N/A
- BANR 2.86%
- EPS Growth
- SUPN 1411.53
- BANR 9.13
- EPS
- SUPN 1.14
- BANR 5.25
- Revenue
- SUPN $665,125,000.00
- BANR $624,024,000.00
- Revenue This Year
- SUPN $4.84
- BANR $0.95
- Revenue Next Year
- SUPN $17.69
- BANR $6.48
- P/E Ratio
- SUPN $40.24
- BANR $12.77
- Revenue Growth
- SUPN 5.55
- BANR 5.10
- 52 Week Low
- SUPN $29.16
- BANR $53.78
- 52 Week High
- SUPN $46.79
- BANR $78.05
- Technical
- Relative Strength Index (RSI)
- SUPN 73.71
- BANR 53.34
- Support Level
- SUPN $44.10
- BANR $66.10
- Resistance Level
- SUPN $46.79
- BANR $68.97
- Average True Range (ATR)
- SUPN 1.06
- BANR 1.53
- MACD
- SUPN -0.17
- BANR 0.01
- Stochastic Oscillator
- SUPN 85.92
- BANR 57.55
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About BANR Banner Corporation
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.